JTT-251 is under clinical development by Japan Tobacco and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect JTT-251’s likelihood of approval (LoA) and phase transition for Congestive Heart Failure (Heart Failure) took place on 23 Sep 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their JTT-251 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

JTT-251 overview

JTT-251 is under development for the treatment of heart failure with reduced ejection fraction. The drug candidate is administered orally as a tablet. It targets pyruvate dehydrogenase kinase. It was also under development for the treatment of pulmonary arterial hypertension and type 2 diabetes mellitus.

Japan Tobacco overview

Japan Tobacco (JT Group) is a tobacco company that manufactures cigarettes. It also manufactures, markets, and sells varied pharmaceutical and processed food products such as frozen cooked rice and noodles, instant noodles, bread, and frozen bread, packaged cooked rice, bakery goods, yeast extracts and seasoning, prescription drugs, and generic drugs. The company distributes its products through supermarkets, street and train station kiosks, convenience stores, small independent retailers, and vending machines. JT Group caters to retail, industrial and commercial customers in Europe, Africa, the Middle East, Asia-Pacific, and the Americas, and other regions. The company manufactures its products in its own facilities in Japan and other countries. JT Group is headquartered in Minato-Ku, Tokyo, Japan.

Quick View JTT-251 LOA Data

Report Segments
  • Innovator
Drug Name
  • JTT-251
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.